<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02571569</url>
  </required_header>
  <id_info>
    <org_study_id>16144</org_study_id>
    <secondary_id>2014-003283-20</secondary_id>
    <nct_id>NCT02571569</nct_id>
  </id_info>
  <brief_title>A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors</brief_title>
  <official_title>A Phase 1, First in Man, Multicenter, Open Label, Single Escalating Dose Study of BAY1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the safety, tolerability and pharmacokinetics of BAY1093884 after Intravenous
      (IV) and subcutaneous (SC) administration of increasing single doses and SC administration of
      multiple doses.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 28, 2015</start_date>
  <completion_date type="Anticipated">August 6, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 9, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants (single dose cohors) with adverse events as measure of safety and tolerability</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>Adverse events including abnormal laboratory findings and local injection site reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma levels of anti-BAY1093884 antibodies</measure>
    <time_frame>Pre-dose, Day 14, 21,28, 43 and 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of BAY1093884 characterized by AUC(0-tlast)</measure>
    <time_frame>Day 0 [pre-dose (within 1 hour), at the end of infusion or injection (=1hr), 2hrs, 4hrs, 8hrs], Days 1, 3, 5, 7, 14, 21, 28, 43, and 56 (for cohorts 3, 4 and I-SC2, S-2, S-3) after the start of infusion</time_frame>
    <description>AUC from time 0 to the last data point &gt; LLOQ (lower limit of quantitation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of BAY1093884 characterized by AUC(0-tlast)/D</measure>
    <time_frame>Day 0 [pre-dose (within 1 hour), at the end of infusion or injection (=1hr), 2hrs, 4hrs, 8hrs], Days 1, 3, 5, 7, 14, 21, 28, 43, and 56 (for cohorts 3, 4 and I-SC2, S-2, S-3) after the start of infusion</time_frame>
    <description>AUC(0-last) divided by dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of BAY1093884 characterized by Cmax</measure>
    <time_frame>Day 0 [pre-dose (within 1 hour), at the end of infusion or injection (=1hr), 2hrs, 4hrs, 8hrs], Days 1, 3, 5, 7, 14, 21, 28, 43, and 56 (for cohorts 3, 4 and I-SC2, S-2, S-3) after the start of infusion</time_frame>
    <description>Maximum observed drug concentration in measured matrix after single dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of BAY1093884 characterized by Cmax/D</measure>
    <time_frame>Day 0 [pre-dose (within 1 hour), at the end of infusion or injection (=1hr), 2hrs, 4hrs, 8hrs], Days 1, 3, 5, 7, 14, 21, 28, 43, and 56 (for cohorts 3, 4 and I-SC2, S-2, S-3) after the start of infusion</time_frame>
    <description>Cmax divided by dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tissue factor pathway inhibitor (TFPI) activity</measure>
    <time_frame>Up to 77 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants (multiple dose cohort) with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 77 days</time_frame>
    <description>Adverse events including abnormal laboratory findings and local injection site reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of anti-BAY1093884 antibodies (multiple dose cohort)</measure>
    <time_frame>Pre-dose, Day 14, 28, 49 and 77</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of BAY1093884 characterized by AUC(0-7d and AUC(0-tau) (multiple dose cohort)</measure>
    <time_frame>Day 0 (prior to start of SC injection) and 8 hrs after start of SC injection, Days 1, 3, 5 and Days 7, and Day 35 (prior to start of SC injection) and 8 hrs after start of SC injection on Day 35; Days 36, 38, 40, 42</time_frame>
    <description>AUC from time 0 to 7d after first and last dose (AUC(0-tau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of BAY1093884 characterized by AUC(0-7d/D and AUC(0-tau)/D after multiple dose</measure>
    <time_frame>Day 0 (prior to start of SC injection) and 8 hrs after start of SC injection, Days 1, 3, 5 and Days 7, and Day 35 (prior to start of SC injection) and 8 hrs after start of SC injection on Day 35; Days 36, 38, 40, 42</time_frame>
    <description>AUC(0-7d) after first dose and AUC(0-tau) after last dose divided by dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of BAY1093884 characterized by Cmax after first dose and last dose (Cmax,md)</measure>
    <time_frame>Day 0 (prior to start of SC injection) and 8 hrs after start of SC injection, Days 1, 3, 5 and Days 7, and Day 35 (prior to start of SC injection) and 8 hrs after start of SC injection on Day 35; Days 36, 38, 40, 42</time_frame>
    <description>maximum observed drug concentration in measured matrix after first and last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of BAY1093884 characterized by Cmax/D after first dose and last dose (Cmax,md/D)</measure>
    <time_frame>Day 0 (prior to start of SC injection) and 8 hrs after start of SC injection, Days 1, 3, 5 and Days 7, and Day 35 (prior to start of SC injection) and 8 hrs after start of SC injection on Day 35; Days 36, 38, 40, 42</time_frame>
    <description>Cmax after first and last dose divided by dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation of BAY 1093884 in plasma as defined by ratio for Cmax and AUC (after first and last dose)</measure>
    <time_frame>Day 0 (prior to start of SC injection) and 8 hrs after start of SC injection, Days 1, 3, 5 and Days 7, and Day 35 (prior to start of SC injection) and 8 hrs after start of SC injection on Day 35; Days 36, 38, 40, 42</time_frame>
    <description>Cmax after last dose divided by Cmax after first dose, AUC after last dose divided by AUC after first dose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>Without inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation steps for participants without inhibitors - intravenous infusion and subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>With inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation steps for participants with inhibitors - intravenous infusion and subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without inhibitors_multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose cohort for participants without inhibitors - a single subcutaneous injection once a week for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1093884</intervention_name>
    <description>Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.</description>
    <arm_group_label>Without inhibitors</arm_group_label>
    <arm_group_label>With inhibitors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1093884</intervention_name>
    <description>Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.</description>
    <arm_group_label>Without inhibitors_multiple dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males with severe congenital Hemophilia A or B defined as &lt;1% FVIII or Factor IX (FIX)
             concentration by measurement at the time of screening or from reliable prior
             documentation

          -  For subjects in Cohorts I-IV, I-SC1 and I-SC2; If history of inhibitors is evident,
             inhibitor titer of ≥5 Bethesda Units (BU) at screening or prior to screening at any
             time from medical records.

          -  Age: 18 to 65 years of age at screening

          -  Body mass index (BMI): 18 to 29.9 kg/m²

        Exclusion Criteria:

          -  Subjects with known bleeding disorders (such as von Willebrand factor [vWF]
             deficiency, FXI deficiency, platelet disorders, or known acquired or inherited
             thrombophilia etc.) other than congenital Hemophilia A or B with or without inhibitors

          -  History of angina pectoris or treatment for angina pectoris

          -  History of coronary and/or peripheral atherosclerotic disease, congestive heart
             failure, disseminated intravascular coagulopathy, or stage 2 hypertension defined as
             systolic blood pressure (SBP) ≥160 mmHg or diastolic blood pressure (DBP) ≥100 mmHg
             even if controlled

          -  History of thrombophlebitis, venous / arterial thromboembolic diseases (particularly
             deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction,
             cerebrovascular accident, ischemic heart disease, transient ischemic attack)

          -  Known or suspected hypersensitivity of the immune system, history of anaphylactic
             reaction, known (clinically relevant) allergies, non-allergic drug reactions, or
             multiple drug allergies
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suginami</city>
        <state>Tokyo</state>
        <zip>167-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

